IL6 and non-small cell lung carcinoma: Using clinical microarray database of NSCLC [39], we found that significantly poorer overall survival (OS) and metastasis free survival (MFS) were observed in NSCLC patients with low HIC1 and high IL-6 expression than the patients with high HIC1 and low IL-6 expression(Supplementary Figure 8A, 8B).